[Field trial with a new human diploid cell vaccine (HDCV) against measles, mumps and rubella].
The results of a field trial with a novel, live attenuated human diploid cell vaccine (HDCV) against measles, mumps and rubella are described. The study was performed double blind and included 120 children aged 15 to 24 months. 60 children received the new vaccine and a control group of another 60 children were vaccinated with M-M-RR II. The seroconversion rates found 6 to 8 weeks after the vaccination were high without exception (95% to 100%). The multiple chi 2-test revealed no statistically significant difference in immunogenic efficacy between the two vaccines (p greater than 0.05). No reports of side effects were received from the 12 physicians participating in the study. It is pointed out that all components of the new vaccine are highly attenuated and that the vaccine is free of avian protein, animal protein extracts and antibiotics. This excludes all theoretical and practical contraindications due to the corresponding hypersensitivities.
D000914:Antibodies, Viral / Q000032:analysis; D004311:Double-Blind Method; D006801:Humans; D007223:Infant; D008457:Measles / Q000276:immunology / Q000517:prevention & control*; D008458:Measles Vaccine / Q000008:administration & dosage* / Q000276:immunology; D009107:Mumps / Q000276:immunology / Q000517:prevention & control*; D009108:Mumps Vaccine / Q000008:administration & dosage* / Q000276:immunology; D012409:Rubella / Q000276:immunology / Q000517:prevention & control*; D012411:Rubella Vaccine / Q000008:administration & dosage* / Q000276:immunology
D000914:Antibodies, Viral; D008458:Measles Vaccine; D009108:Mumps Vaccine; D012411:Rubella Vaccine
Feldversuch mit einer neuartigen Humandiploidzellvakzine (HDCV) gegen Masern, Mumps und Röteln.